Olanzapine + Aripiprazole
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jul 1, 2004 → Aug 1, 2006
NCT ID
NCT00103571About Olanzapine + Aripiprazole
Olanzapine + Aripiprazole is a approved stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00103571. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00103571 | Approved | Completed |
| NCT00088049 | Approved | Completed |
Competing Products
20 competing products in Schizophrenia